|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study used a rat model to test whether prenatal immune activation with lipopolysaccharide (LPS; at gestation days, GD, 15 and 16) or maternal iron deficiency (from GD2 to postnatal day P7) or the combination of both insults alters major subtypes of GABAergic interneurons (parvalbumin, somatostatin, cholecystokinin) in brain regions relevant to schizophrenia (medial and dorsolateral prefrontal cortex [PFC], hippocampal CA1 and dentate gyrus, ventral subiculum) in offspring at P14 or P28.
|
28214898 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients.
|
20732371 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that schizophrenia is associated with alterations in inhibitory inputs from SST/NPY-containing and CCK-containing subpopulations of GABA neurons and in the signaling via certain GABA(A) receptors that mediate synaptic (phasic) or extrasynaptic (tonic) inhibition.
|
17471287 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These findings suggest that schizophrenia is associated with alterations in inhibitory inputs from SST/NPY-containing and CCK-containing subpopulations of GABA neurons and in the signaling via certain GABA(A) receptors that mediate synaptic (phasic) or extrasynaptic (tonic) inhibition.
|
17471287 |
2008 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.
|
18606950 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
While our family-based tests seem to support the CCK involvement in schizophrenia, no definite conclusion can be drawn based on such a small sample size.
|
12116180 |
2002 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia.
|
11549403 |
2001 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tetrapeptide of cholecystokinin (CCK), CCK-4, is known to induce panic attacks in human subjects, while CCK-8 is reported to have a therapeutic effect on schizophrenia symptoms.
|
11803530 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia.
|
11549403 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia.
|
11443535 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder.
|
9491815 |
1998 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In so far as CCK is co-localized with GABA or glutamate in cortical neurons, both of these neuronal populations need to be studied further in schizophrenia and suicide.
|
9278188 |
1997 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The study revealed a marked decrease in CCK mRNA of 83% in frontal cortex (BA10) and 63% in superior temporal cortex (BA22) in schizophrenia with no change in G(o) alpha-subunit mRNA in either region.
|
7640324 |
1995 |